Literature DB >> 36267130

Novel IRAK Degraders for Treating Cancer.

Ram W Sabnis1.   

Abstract

Provided herein are novel compounds used as IRAK4 degraders, their pharmaceutical compositions, the use of such compounds in treating cancer, and processes for preparing such compounds. Published 2022 by American Chemical Society.

Entities:  

Year:  2022        PMID： 36267130      PMCID： PMC9578025          DOI： 10.1021/acsmedchemlett.2c00380

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


  6 in total

Review 1.  Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins.

Authors:  Cédric Zeltz; Irina Primac; Pugazendhi Erusappan; Jahedul Alam; Agnes Noel; Donald Gullberg
Journal:  Semin Cancer Biol       Date:  2019-08-12       Impact factor: 15.707

Review 2.  Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.

Authors:  Jia-Yue Xi; Ru-Yue Zhang; Ke Chen; Lin Yao; Mu-Qiong Li; Ru Jiang; Xiao-Ye Li; Li Fan
Journal:  Bioorg Chem       Date:  2022-05-05       Impact factor: 5.275

Review 3.  Interleukin-1 signaling in solid organ malignancies.

Authors:  Austin R Dosch; Samara Singh; Nagaraj S Nagathihalli; Jashodeep Datta; Nipun B Merchant
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2021-12-16       Impact factor: 10.680

Review 4.  Tumor-associated neutrophils and neutrophil-targeted cancer therapies.

Authors:  Haiying Que; Qianmei Fu; Tianxia Lan; Xiaohe Tian; Xiawei Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2022-07-16       Impact factor: 11.414

Review 5.  NF-κB signaling in inflammation and cancer.

Authors:  Tao Zhang; Chao Ma; Zhiqiang Zhang; Huiyuan Zhang; Hongbo Hu
Journal:  MedComm (2020)       Date:  2021-12-16

Review 6.  Pyrrolo[2,1-f][1,2,4]triazine: a promising fused heterocycle to target kinases in cancer therapy.

Authors:  Sarbjit Singh; Divya Utreja; Vimal Kumar
Journal:  Med Chem Res       Date:  2021-11-13       Impact factor: 1.965
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.